ProCE Banner Activity

Considerations for Relapsed/Refractory MM After Multiple Lines of Therapy

Slideset Download
Download these slides from a live symposium for a summary of current considerations for patients with relapsed/refractory myeloma who have received multiple previous lines of therapy.

Released: December 09, 2022

Expiration: December 08, 2023

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Janssen administered by Scientific Affairs

Karyopharm Therapeutics Inc.

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc.

Takeda Pharm USA

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota